Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine for Prescription Opioid Dependence
NCT02187198Phase 3Completed
- Sponsor
- Yale University
- Start
- Mar 2015
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) (2 arms), sponsored by Yale University. Primary endpoints: Urine Toxicology for Opiate Use and Urine Toxicology. Started Mar 2015; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT02187198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02187198.